Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis

British Journal of Cancer

Volumn 111, Issue 5, 2014, Pages 918-926

  Rosin, G ^a   De Boniface, J ^a,b   Karthik, G M ^a   Frisell, J ^a,b   Bergh, J ^a,b   Hartman, J ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

biomarkers; breast cancer; endocrine therapy; oestrogen receptor; oncology; pathology

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETACX; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SPECIFIC SURVIVAL; CLINICAL FEATURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENTINEL LYMPH NODE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84906938980     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.398     Document Type: Article

References (36)

1. Andersson Y, de Boniface J, Jönsson PE, Ingvar C, Liljegren G, Bergkvist L, Frisell J. Swedish Breast Cancer Group, Swedish Society of Breast Surgeons (2012) Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg 99: 226-231.
2. Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L (2010) Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol 28: 2868-2873.
3. Bentzon N, Düring M, Rasmussen BB, Mouridsen H, Kroman N (2008) Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 122: 1089-1094.
4. Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirström K (2008) Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 61: 197-203.
5. Carder PJ, Murphy CE, Dervan P, Kennedy M, McCann A, Saunders PTK, Shaaban AM, Foster CS, Witton CJ, Bartlett JMS, Walker RA, Speirs V (2005) A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERb in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat 92: 287-293.
6. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147: 4831-4842.
7. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771-784.
8. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. an NSABP update. Cancer 52: 1551-1557.
9. Fuqua SAW, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63: 2434-2439.
10. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A, Fernö M (2007) Estrogen receptor expression is associated with tamoxifen response in ER-negative breast carcinoma. Clin Cancer Res 13: 1987-1994.
11. Gschwantler-Kaulich D, Fink-Retter A, Czerwenka K, Hudelist G, Kaulich A, Kubista E, Singer CF (2011) Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases. Tumour Biol 32: 501-508.
12. Hartman J, Lindberg K, Morani A, Inzunza J, Ström A, Gustafsson J-A (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66: 11207-11213.
13. Hartman J, Ström A, Gustafsson J-A (2009) Estrogen receptor beta in breast cancer - diagnostic and therapeutic implications. Steroids 74: 635-641.
14. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481.
15. Hill L, Jeganathan V, Chinnasamy P, Grimaldi C, Diamond B (2011) Differential roles of estrogen receptors a and b in control of B-cell maturation and selection. Mol Med 17: 211-220.
16. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26: 3727-3734.
17. Krecsák L, Micsik T, Kiszler G, Krenács T, Szabó D, Jónás V, Császár G, Czuni L, Gurzó P, Ficsor L, Molnár B (2011) Technical note on the validation of a semi-automated image analysis software application for estrogen and progesterone receptor detection in breast cancer. Diagn Pathol 6: 6.
18. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930.
19. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263.
20. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y, Younes M (2001) Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32: 113-118.
21. Marotti JD, Collins LC, Hu R, Tamimi RM (2009) Estrogen receptor. Mod Pathol 23: 197-204.
22. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 10: R74.
23. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 26: 3505-3512.
24. Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson JA, Iwase H (2002) Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38: 380-386.
25. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61: 2537-2541.
26. Rosin G, Hannelius U, Lindström L, Hall P, Bergh J, Hartman J, Kere J (2012) The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer. BMC Cancer 12: 79.
27. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin S-F, Palmieri C, Caldas C, Carroll JS (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481: 389-393.
28. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PTK, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ER 1, ER 2, and ER 5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14: 5228-5235.
29. Shim G-J, Gherman D, Kim H-J, Omoto Y, Iwase H, Bouton D, Kis LL, Andersson CT, Warner M, Gustafsson J-A (2006) Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol 208: 408-414.
30. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V (2002) Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 197: 155-162.
31. Sorlie T,Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale A-L (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7: 127.
32. Speirs V, Skliris GP, Burdall SE, Carder PJ (2002) Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55: 371-374.
33. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson J-A (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101: 1566-1571.
34. Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165: 710-718.
35. Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH, Murphy LC (2006) Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res 100: 23-31.
36. Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, Lam EW-F, Cheng G, Gustafsson JA, Dahlman-Wright K (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67: 3955-3962.